Astellas Pharma Inc. (4503.T) stock analysis

In our weekly check, Astellas Pharma Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 3, red flags: 3.

About Astellas Pharma Inc.

Astellas Pharma Inc. is a Healthcare company (Drug Manufacturers - General) based in Japan, listed on JPX as 4503.T.

What our checks show for 4503.T

Red flags

• The gross margin fell by 5.8 points, to 74.7%: costs are rising faster than prices.
• Analysts expect revenue to shrink about 5.1% a year.
• Analysts expect the net margin to shrink by 3.6 points from today's 16%.

Warning signs

• Analysts expect earnings per share to shrink about 8.4% a year.
• The stock has fallen as much as 50% from a peak. Would you have held through that?
• Recovering from its deepest fall took about 1.6 years.

Strengths

• Net debt is only 0.5x a year of EBITDA: the balance sheet has room.
• Operating profit covers interest 43.9 times over.
• The net margin rose by 6.5 points over 5 years, to 16%.
• Operating cash flow is 1.64x net profit: the profit arrives as real cash.
• Earnings per share grew 55.4% a year over the last 3 years.
• Net profit grew 54.6% a year over the last 3 years.

Next earnings report: 2026-11-04

Similar companies

4568.T · 4578.T · 4519.T · LLY · JNJ · ABBV

Questions

What grade does Astellas Pharma Inc. (4503.T) have?

In our weekly check, Astellas Pharma Inc. is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 19 pass, warnings: 3, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 4503.T stock?

This week's biggest flags for Astellas Pharma Inc.: Gross margin falling, Weak revenue forecast, Margins expected to shrink. In total 6 of 25 checks show a warning or a red flag.

What does Astellas Pharma Inc. do?

Astellas Pharma Inc. is a Healthcare company (Drug Manufacturers - General) based in Japan, listed on JPX as 4503.T.

When does Astellas Pharma Inc. report earnings next?

The next earnings report is expected on 2026-11-04. We re-run the checks every week, so the grade can change after it.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis